168053 20260202145620.0 doi 10.1016/j.metabol.2013.10.014 sideral 85224 ART-2014-85224 eng Cenarro, A. Effect of nicotinic acid/Laropiprant in the Lipoprotein(a) concentration with regard to baseline lipoprotein(a) concentration and LPA genotype 2014 Background: Lipoprotein(a) [Lp(a)] is a lipoprotein in which apolipoproteinB-100 is linked to apolipoprotein(a) [apo(a)]. Significant variation in Lp(a) concentration is specific to LPA gene, which codes for apo(a). Nicotinic acid (NA) is used for treatment of dyslipidemias, and the lowering effect of NA on Lp(a) has been previously reported. Objective: To evaluate the Lp(a) lowering effect of 1 g/20 mg and 2 g/40 mg day of Nicotinic acid/Laropiprant in subjects with different baseline Lp(a) concentrations and depending on the LPA genotype. Methods: In an open-label, 10-week study, 1 g/20 mg day of NA/Laropiprant for 4 weeks followed by 6 weeks of 2 g/40 mg day conducted at 3 centers in Spain, 82 subjects were enrolled. Patients were studied at baseline and at the end of both treatment periods and were enrolled in three groups: normal Lp(a) (< 50 mg/dL), high Lp(a) (50–120 mg/dL) and very high Lp(a) (> 120 mg/dL). The LPA genetic polymorphism was analyzed by a real-time PCR. Results: There was a significant difference in LPA genotypes among Lp(a) concentration groups and an inverse and significant correlation between baseline Lp(a) concentration and LPA genotype was found (R = − 0.372, p < 0.001). There were a significant decrease in total cholesterol, triglycerides, LDL cholesterol, apo B and Lp(a), and a significant increase in HDL cholesterol after NA/Laropiprant treatment, without changes in BMI. However, there were no statistical differences in percentage variation of analyzed variables depending on LPA genotype. Conclusion: LPA genotype is a major determinant of Lp(a) baseline concentration. However, the lipid lowering effect of NA is not related to LPA genotype. info:eu-repo/semantics/closedAccess All rights reserved http://www.europeana.eu/rights/rr-f/ 3.894 2014 ENDOCRINOLOGY & METABOLISM 39 / 128 = 0.305 2014 Q2 T1 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Puzo, J. Universidad de Zaragoza (orcid)0000-0002-1309-4363 Ferrando, J. Mateo-Gallego, R. (orcid)0000-0001-6650-8294 Bea, A. M. Calmarza, P. Jarauta, E. Universidad de Zaragoza (orcid)0000-0001-9142-0737 Civeira, F. Universidad de Zaragoza (orcid)0000-0001-7043-0952 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 63, 3 (2014), 365-371 Metab. clin. exp. METABOLISM-CLINICAL AND EXPERIMENTAL 0026-0495 507874 http://zaguan.unizar.es/record/168053/files/texto_completo.pdf Versión publicada 2247684 http://zaguan.unizar.es/record/168053/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:168053 articulos driver 2026-02-02-14:49:02 ARTICLE